Drug Type Monoclonal antibody |
Synonyms HLX 55, KTN-0216, KTN0216 |
Target |
Action inhibitors |
Mechanism c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
License Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | Taiwan Province | 03 Mar 2020 | |
| Liver Cancer | IND Approval | China | 10 Aug 2019 | |
| Lung Cancer | IND Approval | China | 10 Aug 2019 | |
| Stomach Cancer | IND Approval | China | 10 Aug 2019 | |
| Glioblastoma | Preclinical | China | 13 Dec 2018 |






